Results 101 to 110 of about 2,631,955 (205)

Image_2_Association of LRP1B Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades.TIFF

, 2019
Background: Tumor mutation burden (TMB) have been served as the most prevalent biomarkers to predict immunotherapy response. LRP1B (low-density lipoprotein receptor-related protein 1B) is frequently mutated in melanoma, non-small cell lung cancer (NSCLC)
Qian Wu (209382), Hao Chen (5190), Yueliang Yao (2153293), Xin Wang (91924), Min Mao (646400), Wei Chong (782416)   +5 more
core   +1 more source

Image_7_Association of LRP1B Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades.TIFF

, 2019
Background: Tumor mutation burden (TMB) have been served as the most prevalent biomarkers to predict immunotherapy response. LRP1B (low-density lipoprotein receptor-related protein 1B) is frequently mutated in melanoma, non-small cell lung cancer (NSCLC)
Qian Wu (209382), Hao Chen (5190), Yueliang Yao (2153293), Xin Wang (91924), Min Mao (646400), Wei Chong (782416)   +5 more
core   +1 more source

Image_8_Association of LRP1B Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades.TIFF

, 2019
Background: Tumor mutation burden (TMB) have been served as the most prevalent biomarkers to predict immunotherapy response. LRP1B (low-density lipoprotein receptor-related protein 1B) is frequently mutated in melanoma, non-small cell lung cancer (NSCLC)
Qian Wu (209382), Hao Chen (5190), Yueliang Yao (2153293), Xin Wang (91924), Min Mao (646400), Wei Chong (782416)   +5 more
core   +1 more source

Low tumor purity is associated with poor prognosis, heavy mutation burden, and intense immune phenotype in colon cancer

, 2018
Yihao Mao,1,* Qingyang Feng,1,2,* Peng Zheng,1,* Liangliang Yang,1,* Tianyu Liu,1 Yuqiu Xu,1 Dexiang Zhu,1,2 Wenju Chang,1,2 Meiling Ji,1,2 Li Ren,1,2 Ye Wei,1,2 Guodong He,1,2 Jianmin Xu1,2 1Department of General Surgery, Zhongshan Hospital, Fudan ...
Yang L, He G, Zheng P, Liu T, Wei Y, Zhu D, Xu J, Chang W, Ji M, Ren L, Mao Y, Feng Q, Xu Y   +12 more
core  

Low tumor mutational burden and immunotherapy in gliomas

Trends in Cancer, 2022
Brown, Michael C., Ashley, David M., Khasraw, Mustafa   +2 more
openaire   +2 more sources

The Psychosocial Burden of LI-Fraumeni Syndrome Tumor Surveillance on Mutation and Non-Mutation Carriers Within Families [PDF]

, 2020
Individuals undergoing Li-Fraumeni syndrome (LFS) tumor surveillance are known to experience a significant psychosocial burden due to financial, emotional and logistical stresses.
Berenson, Emily Anne
core  

Integrative Analysis of Novel Ferroptosis‐Related Genes Signatures as Prognostic Biomarkers in Ovarian Cancer

Cancer Reports
Background Ferroptosis, an iron‐dependent form of cell death, has been implicated in the pathogenesis of several types of cancer. Nevertheless, the exact correlation between ferroptosis‐related gene mutations and their influence on ovarian cancer (OV ...
Leilei Cao, Yiqin Ouyang, Wei Lu, Xiao Qi, Zhijie Wang, Jingshuai Wang   +5 more
doaj   +1 more source

Tumor mutational burden in colorectal cancer: Implications for treatment

Critical Reviews in Oncology/Hematology
Although immune checkpoint inhibitors have revolutionized the treatment of several advanced solid cancers, in colorectal cancer, the transformative benefit of these innovative medicines is currently limited to those with deficient mismatch repair or high microsatellite instability.
Adriana, Marques, Patrícia, Cavaco, Carla, Torre, Bruno, Sepodes, João, Rocha   +4 more
openaire   +2 more sources

Presence of liver metastasis correlated with high tumor abundance and indicated adverse prognostic feature in EGFR mutation non-small-cell lung cancer patients

Scientific Reports
EGFR-TKIs are effective therapies for non–small cell lung cancer (NSCLC) patients with EGFR-activating mutations. However, responses vary within individuals and resistant disease inevitably emerges. A prospective cohort of 130 patients with advanced EGFR
Piyada Sitthideatphaiboon, Pronwasun Simseekeaw, Chinachote Teerapakpinyo, Nicha Zungsontiporn, Wariya Chintanapakdee, Itthi Itthisawatpan, Shanop Shuangshoti, Virote Sriuranpong, Thanisa Tongbai, Chanida Vinayanuwattikun   +9 more
doaj   +1 more source

Tumor Mutational Burden as a Prognostic Biomarker in Follicular Lymphoma

Cancers
Introduction: Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma. Approximately 20% of patients experience early relapse within 24 months (POD24) of immunochemotherapy (ICT), a subgroup associated with poor prognosis and not well-identified by current prognostic indices.
Marta Lafuente, Ramón Diez-Feijóo, Marta García-Recio, Nieves Garcia-Gisbert, Maria Concepción Fernández-Rodríguez, Raquel Longarón, Junjie Ji, Bárbara Tazon-Vega, Sergio Pinzón, Lierni Fernández-Ibarrondo, Blanca Sánchez-González, Laura Camacho, Joan Gibert, Antonio Gutierrez, Beatriz Bellosillo, Antonio Salar   +15 more
openaire   +3 more sources